Methods to block IGE binding to cell surface receptors of mast cells
US6299875A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jun 4, 1998 |
| Grant date | Oct 9, 2001 |
| Priority date | — |
| Expiry date | Jun 4, 2018 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/866
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions are administered to block IgE binding to receptors and ultimately displace native IgE from mast cells and related cell types, to prevent the activation of these cells during an allergic response. The compositions consist of a pharmaceutically acceptable carrier for systemic or local administration and an amount of compound binding specifically to the Fc.epsilon.RI IgE binding sites, and more preferably, Fc.epsilon.RI and Fc.epsilon.RII IgE binding sites, to prevent activation and degranulation of mast cells in response to exposure to allergens. The compounds can consist of IgE molecules and fragments and modifications thereof, such as IgE fragments, humanized or single chain IgE antibodies or fragments thereof, IgE with a modified Fab, non-crosslinkable IgE, or peptidomimetics which bind to the same site on the receptor as the IgE, jointly referred to herein as "IgE fragments" unless otherwise stated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.